Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | STEAP1 |
| Clinical data | |
| Other names | RG7450 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6608H10168N1756O2076S44 |
| Molar mass | 148838.89 g·mol−1 |
This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3]
References
edit- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association.
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
- ^ "Vandortuzumab vedotin". AdisInsight. Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |